| Host: |
HEK293 cells |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
2019-nCoV S1+S2-C-His protein was developed from hek293 cells and has a target region of C-His. For use in research applications. |
| Formulation: |
Supplied as a 0.22 Mu m filtered solution in PBS, pH 7.4. Contact us for customized product form or formulation. |
| Immunoreactivity: |
Measured by its binding ability in a functional ELISA. Immobilized Recombinant SARS-CoV-2 Spike S1+S2 ECD-His at 2 Mu g/mL (100 Mu L/well) can bind Recombinant Human ACE2 with a linear range of 0.15-9.92 ng/mL. |
| Immunogen Region: |
S-ECD |
| Immunogen: |
Recombinant SARS-COV-2 Spike S1+S2 ECD (S-ECD) Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Val11-Gln1208) of SARS-COV-2 (2019-nCoV) S1+S2 ECD (S-ECD) (Accession #YP_009724390.1) fused with a 6 |
| Background | Active Recombinant SARS-COV-2 Spike S1+S2 ECD (S-ECD) Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Val11-Gln1208) of SARS-COV-2 (2019-nCoV) S1+S2 ECD (S-ECD) (Accession #YP_009724390.1) fused with a 6×His tag at the C-terminus. |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
